HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma

Clinical Biochemistry

Volumn 43, Issue 6, 2010, Pages 545-548

  Kruszyna, Łukasz ^a   Lianeri, Margarita ^a   Roszak, Andrzej ^b   Jagodziński, PaweŁ P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Greater Poland Cancer Centre Poznan   (Poland)

Author keywords

Cervical carcinoma; HER2 Ile655Val polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ISOLEUCINE; VALINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER INCIDENCE; CODON; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AMINO ACID SUBSTITUTION; CARCINOMA; CASE-CONTROL STUDIES; CODON; FEMALE; GENE FREQUENCY; GENETIC TESTING; GENOTYPE; HUMANS; INCIDENCE; ISOLEUCINE; LINKAGE (GENETICS); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; UTERINE CERVICAL NEOPLASMS; VALINE;

EID: 77950858179     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.12.016     Document Type: Article

References (44)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA. Cancer J. Clin. 2005, 55:74-108.
2. Long H.J., Bundy B.N., Grendys E.C., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2005, 23:4626-4633.
3. Ota T., Takeshima N., Tabata T., Hasumi K., Takizawa K. Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers. Br. J. Cancer 2007, 97:1058-1062.
4. Bellone S., Frera G., Landolfi G., et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol. Oncol. 2007, 106:513-520.
5. Muñoz N., Bosch F.X., de Sanjosé S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348:518-527.
6. Costa M.J., Walls J., Trelford J.D. C-erbB-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease. Am. J. Clin. Pathol. 1995, 104:634-642.
7. Niibe Y., Nakano T., Ohno T., Suzuki Y., Oka K., Tsujii H. Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int. J. Gynecol. Cancer 2003, 13:849-855.
8. Prenzel N., Fischer O.M., Streit S., Hart S., Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 2001, 8:11-31.
9. Qian X., Dougall W.C., Hellman M.E., Greene M.I. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. Oncogene 1994, 9:1507-1514.
10. Harari D., Tzahar E., Romano J., et al. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999, 18:2681-2689.
11. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
12. Katz M., Amit I., Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim. Biophys. Acta 2007, 1773:1161-1176.
13. Kokai Y., Myers J.N., Wada T., et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 1989, 58:287-292.
14. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell. Biol. 2006, 7:505-516.
15. Papewalis J., Nikitin A., Rajewsky M.F. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res. 1991, 19:5452.
16. Tommasi S., Fedele V., Lacalamita R., Crapolicchio A., Perlino E., Bellizzi A., Paradiso A. Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Lett. 2004, 209:215-222.
17. Benusiglio P.R., Lesueur F., Luccarini C., et al. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res. 2005, 7:204-209.
18. Tao W., Wang C., Han R., Jiang H. HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res. Treat. 2009, 114:371-376.
19. Ueda M., Hung Y.C., Terai Y., Saito J., Nunobiki O., Noda S., Ueki M. HER-2 codon 655 polymorphism in cervical carcinogenesis. Int. J. Gynecol. Cancer 2006, 16:325-328.
20. Lee S.C., Hou M.F., Hsieh P.C., et al. A case-control study of the HER2 Ile655val polymorphism and risk of breast cancer in Taiwan. Clin. Bioch. 2008, 41:121-125.
21. Meira D.D., de Almeida V.H., Mororó J.S., et al. Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br. J. Cancer 2009, 101:782-791.
22. Sharma P.S., Sharma R., Tyagi T. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr. Pharm. Des. 2009, 15:758-776.
23. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
24. Vincenzi B., Schiavon G., Silletta M., Santini D., Tonini G. The biological properties of cetuximab. Crit. Rev. Oncol. Hematol. 2008, 68:93-106.
25. Semba K., Kamata N., Toyoshima K., Yamamoto T.A. v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc. Nat. Acad. Sci. 1985, 82:6497-6501.
26. Mitra A.B., Murty V.V., Pratap M., Sodhani P., Chaganti R.S. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res. 1994, 54:637-639.
27. Fuchs I., Vorsteher N., Bühler H., et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res. 2007, 27:959-963.
28. Samouelian V., Revillion F., Alloy N., Lhotellier V., Leblanc E., Peyrat J.P. Measurement of mRNA of 11 biomarkers by RT-PCR to detect lymph node involvement in cervical cancer. Int. J. Biol. Markers 2008, 23:74-82.
29. Rosty C., Couturier J., Vincent-Salomon A., et al. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. Int. J. Gynecol. Pathol. 2004, 23:13-17.
30. Yamashita H., Murakami N., Asari T., Okuma K., Ohtomo K., Nakagawa K. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:1165-1172.
31. Lesnikova I., Lidang M., Hamilton-Dutoit S., Koch J. HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. APMIS 2009, 117:737-745.
32. Chavez-Blanco A., Perez-Sanchez V., Gonzalez-Fierro A., et al. HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004, 4:59.
33. Frank B., Hemminki K., Wirtenberger M., et al. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis 2005, 26:643-647.
34. Xie D., Shu X.O., Deng Z., et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J. Natl. Cancer Inst. 2000, 92:412-417.
35. Millikan R., Eaton A., Worley K., et al. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res. Treat. 2003, 79:355-364.
36. Montgomery K.G., Gertig D.M., Baxter S.W., et al. The HER2 I655V polymorphism and risk of breast cancer in women age 40 years. Cancer Epidemiol. Biomarkers Prev. 2003, 12:1109-1111.
37. Keshava C., McCanlies E.C., Keshava N., Wolff M.S., Weston A. Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett. 2001, 173:37-41.
38. Rutter J.L., Chatterjee N., Wacholder S., Struewing J. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology 2003, 14:694-700.
39. Kamali-Sarvestani E., Talei A.R., Merat A. Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett. 2004, 215:83-87.
40. Bargmann C.I., Hung M.C., Weinberg R.A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986, 45:649-657.
41. Segatto O., King C.R., Pierce J.H., Di Fiore P.P., Aaronson S.A. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol. Cell. Biol. 1988, 8:5570-5574.
42. Sternberg M.J., Gullick W.J. A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Eng. 1990, 3:245-248.
43. Fleishman S.J., Schlessinger J., Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:15937-15940.
44. Laferriere J., Houle F., Huot J. Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38. Ann. N. Y. Acad. Sci. 2002, 973:562-572.